Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2022).
Google Scholar
Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034–2044 (2023).
Google Scholar
Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491–502 (2021).
Google Scholar
Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019).
Google Scholar
Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).
Google Scholar
Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).
Google Scholar
Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).
Google Scholar
Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212–2221 (2019).
Google Scholar
Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T-cells. Blood 142, 1243–1248 (2023).
Google Scholar
Wudhikarn, K. et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 4, 3024–3033 (2020).
Google Scholar
Rejeski, K. et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J. Hematol. Oncol. 16, 88 (2023).
Google Scholar
Rejeski, K. et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am. J. Hematol. 98, 1699–1710 (2023).
Google Scholar
Jain, T. et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 4, 3776–3787 (2020).
Google Scholar
Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138, 2499–2513 (2021).
Google Scholar
Hill, J. A. et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131, 121–130 (2018).
Google Scholar
Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J. Immunother. Cancer 10, e004475 (2022).
Google Scholar
Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood 140, 349–358 (2022).
Google Scholar
Kampouri, E. et al. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl. Infect. Dis. 25, e14157 (2023).
Google Scholar
Gudiol, C., Lewis, R. E., Strati, P. & Kontoyiannis, D. P. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 8, e216–e228 (2021).
Google Scholar
Hines, M. R. et al. Immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Transpl. Cell Ther. 29, 438.e1–438.e16 (2023).
Google Scholar
Cordeiro, A. et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 26, 26–33 (2020).
Google Scholar
Zhao, A. et al. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: case series and review of literature. Front. Immunol. 13, 1063986 (2022).
Google Scholar
Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338–341 (2024).
Google Scholar
Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984–989 (2024).
Google Scholar
Storgard, R., Rejeski, K., Perales, M. A., Goldman, A. & Shouval, R. T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. (2024).
Chakraborty, R., Hill, B. T., Majeed, A. & Majhail, N. S. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transpl. Cell Ther. 27, 222–229 (2021).
Google Scholar
Strati, P. et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137, 3272–3276 (2021).
Google Scholar
Rejeski, K. et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci. Adv. 9, eadg3919 (2023).
Google Scholar
Jacobs, M. T. et al. Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US Lymphoma CAR-T Consortium. Clin. Lymphoma Myeloma Leuk. 22, 753–759 (2022).
Google Scholar
Brammer, J. E. et al. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J. Immunother. Cancer 9, e002303 (2021).
Google Scholar
Lemoine, J. et al. Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 7, 6589–6598 (2023).
Google Scholar
McDonald, G. B. et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann. Intern Med. 172, 229–239 (2020).
Google Scholar
Dreyling, M. et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood 143, 1713–1725 (2024).
Google Scholar
Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91–103 (2022).
Google Scholar
Abramson, S. J. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Google Scholar
Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629–639 (2022).
Google Scholar
Houot, R. et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat. Med. 29, 2593–2601 (2023).
Google Scholar
Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294–2308 (2022).
Google Scholar
Kato, K. et al. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int. J. Clin. Oncol. 27, 213–223 (2022).
Google Scholar
Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735–742 (2022).
Google Scholar
Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307–2315 (2023).
Google Scholar
Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23, 1066–1077 (2022).
Google Scholar
Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148–157 (2023).
Google Scholar
Lin, Y. et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat. Med. 29, 2286–2294 (2023).
Google Scholar
Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265–1274 (2023).
Google Scholar
Mi, J. Q. et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41, 1275–1284 (2023).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Google Scholar
Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002–1014 (2023).
Google Scholar
San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023).
Google Scholar
Wang, Y. et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 41, 2594–2606 (2023).
Google Scholar
Hamilton, M. P. et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. (2024).
Berning, P. et al. Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: a multicenter cohort study. Hemasphere 8, e54 (2024).
Google Scholar
Chiappella, A. et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia 38, 1107–1114 (2024).
Google Scholar
De Philippis, C. et al. Out of specification tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transpl. 59, 569–571 (2024).
Google Scholar
Dores, G. M., Jason, C., Niu, M. T. & Perez-Vilar, S. Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. Am. J. Hematol. 96, 1087–1100 (2021).
Google Scholar
Grana, A. et al. Safety of axicabtagene xiloleucel for the treatment of relapsed or refractory large B-cell lymphoma. Clin. Lymphoma Myeloma Leuk. 21, 238–245 (2021).
Google Scholar
Iovino, L. et al. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study. J. Cell Mol. Med. 26, 5976–5983 (2022).
Google Scholar
Jacobson, C. A. et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl. Cell Ther. 28, 581.e581–581.e588 (2022).
Kuhnl, A. et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma—the UK real-world experience. Br. J. Haematol. 198, 492–502 (2022).
Google Scholar
Kwon, M. et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica 108, 110–121 (2023).
Google Scholar
Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 38, 3119–3128 (2020).
Google Scholar
Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transpl. Cell Ther. 28, 669–676 (2022).
Google Scholar
Spanjaart, A. M. et al. The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands. Cancers 15, 4334 (2023).
Google Scholar
Trando, A. et al. Outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL): a single-institution experience. Cancers 15, 4671 (2023).
Google Scholar
Wudhikarn, K. et al. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 7, 3192–3198 (2023).
Google Scholar
Akhtar, O. S. et al. Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transpl. Cell Ther. 30, 283.e281–283.e210 (2024).
Google Scholar
Caillot, L. et al. Early chimeric antigen receptor T cell expansion is associated with prolonged progression-free survival for patients with relapsed/refractory multiple myeloma treated with Ide-Cel: a retrospective monocentric sudy. Transplant Cell Ther. (2024).
Ferreri, C. J. et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 13, 117 (2023).
Google Scholar
Fischer, L. et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. Leukemia 38, 372–382 (2024).
Google Scholar
Hansen, D. K. et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J. Clin. Oncol. 41, 2087–2097 (2023).
Google Scholar
Chong, E. A. et al. Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma. Transplant Cell Ther. (2024).
Iacoboni, G. et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 6, 3606–3610 (2022).
Google Scholar
Wang, M. et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J. Clin. Oncol. 41, 555–567 (2023).
Google Scholar
Crowther, M., Lim, W. & Crowther, M. A. Systematic review and meta-analysis methodology. Blood 116, 3140–3146 (2010).
Google Scholar
Little, J. S. et al. Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy. Blood Adv. 7, 5485–5495 (2023).
Google Scholar
Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675–1684 (2023).
Google Scholar
Sehgal, A. R. et al. Lisocabtagene maraleucel as second-line therapy for R/R large B-cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 PILOT study. Blood 142, 105–105 (2023).
Google Scholar
Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022).
Google Scholar
Rejeski, K. et al. Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Cancer Immunol. Res. 11, 707–719 (2023).
Google Scholar
Dos Santos, D. M. C. et al. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica 107, 2096–2107 (2022).
Google Scholar
Shouse, G. et al. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 7, 3516–3529 (2023).
Google Scholar
Bucklein, V. et al. Inferior outcomes of EU versus US patients treated with CD19 CAR-T for telapsed/tefractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use. Hemasphere 7, e907 (2023).
Google Scholar
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
Google Scholar
Al Hadidi, S. & Cliff, E. R. S. CARTIFAN-1: concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. Eur. J. Cancer 182, 1–2 (2023).
Google Scholar
Hill, J. A. & Seo, S. K. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136, 925–935 (2020).
Google Scholar
Busca, A. et al. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 6, 2427–2433 (2022).
Google Scholar
Spanjaart, A. M. et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia 35, 3585–3588 (2021).
Google Scholar
Boyle, S. et al. Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time. Br. J. Haematol. 204, 507–513 (2024).
Google Scholar
Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med. 30, 507–518 (2024).
Google Scholar
Filosto, S. et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21–33 (2024).
Google Scholar
Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3, 2812–2815 (2019).
Google Scholar
Rejeski, K., Jain, M. D. & Smith, E. L. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transpl. Cell Ther. 29, 418–428 (2023).
Google Scholar
El Chaer, F., Auletta, J. J. & Chemaly, R. F. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. Blood 140, 673–684 (2022).
Google Scholar
Goodman, K. A. et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J. Clin. Oncol. 26, 5240–5247 (2008).
Google Scholar
Danylesko, I. & Shimoni, A. Second malignancies after hematopoietic stem cell transplantation. Curr. Treat. Options Oncol. 19, 9 (2018).
Google Scholar
Saleem, K. et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 9, e906–e918 (2022).
Google Scholar
Hill, B. T. et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br. J. Haematol. 152, 561–569 (2011).
Google Scholar
Panagiota, V. et al. Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients. Hemasphere 7, e957 (2023).
Google Scholar
Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982–2986 (2021).
Google Scholar
Challen, G. A. & Goodell, M. A. Clonal hematopoiesis: mechanisms driving dominance of stem cell clones. Blood 136, 1590–1598 (2020).
Google Scholar
Asada, S. & Kitamura, T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 112, 3962–3971 (2021).
Google Scholar
Goldman, A. et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J. Am. Coll. Cardiol. 78, 1800–1813 (2021).
Google Scholar
Hashmi, H. et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 4, 4086–4090 (2020).
Google Scholar
Booth, C. M., Karim, S. & Mackillop, W. J. Real-world data: towards achieving the achievable in cancer care. Nat. Rev. Clin. Oncol. 16, 312–325 (2019).
Google Scholar
Vera-Badillo, F. E. et al. Bias in reporting of randomised clinical trials in oncology. Eur. J. Cancer 61, 29–35 (2016).
Google Scholar
Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 1403–1415 (2021).
Google Scholar
Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142, 865–877 (2023).
Google Scholar
Rejeski, K. et al. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere 7, e889 (2023).
Google Scholar
Rejeski, K. et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 8, 1857–1868 (2024).
Google Scholar
Lievin, R. et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transpl. 57, 431–439 (2022).
Google Scholar
Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022).
Google Scholar
Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst. Rev. 10, 1–11 (2021).
Google Scholar
Munn, Z. et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid. Synth. 18, 2127–2133 (2020).
Google Scholar
Easterbrook, P. J., Gopalan, R., Berlin, J. & Matthews, D. R. Publication bias in clinical research. Lancet 337, 867–872 (1991).
Google Scholar
Schwarzer, G. meta: an R package for meta-analysis. R News 7, 40–45 (2007).
Newcombe, R. G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17, 857–872 (1998).
Google Scholar
Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557–560 (2003).
Google Scholar
Hardy, R. J. & Thompson, S. G. A likelihood approach to meta-analysis with random effects. Stat. Med. 15, 619–629 (1996).
Google Scholar
Knapp, G. & Hartung, J. Improved tests for a random effects meta-regression with a single covariate. Stat. Med. 22, 2693–2710 (2003).
Google Scholar
Higgins, J. P. T. & Thompson, S. G. Controlling the risk of spurious findings from meta-regression. Stat. Med. 23, 1663–1682 (2004).
Google Scholar
Higgins, J. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) (Cochrane, 2023); www.training.cochrane.org/handbook
